Cohen SB, et al. - Authors conducted this study to demonstrate the efficacy, safety, and immunogenicity [antidrug antibodies (ADAs), ADA titres and neutralizing antibodies] of adalimumab biosimilar candidate BI 695501 with Humira in subjects with moderately to severely active rheumatoid arthritis. They found that BI 695501 vs Humira had similar efficacy, safety, and immunogenicity. No effect on the efficacy, safety, and immunogenicity was noted after switching from Humira to BI 695501.